Both the CXCR5 and CCR6 single-expression groups showed a notable enhancement in anti-tumor effects over the HER2-CAR T group, with no significant difference between the two single-expression groups (final tumor bioluminescence photon flux: 45,520 ± 10,305.68 p/s for CXCR5 and 46,760 ± 13,614.07 p/s for CCR6). This evidence concerns the gene ERBB2 and neoplasm.